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Abstract
Aim—Peripheral blood-derived endothelial cells (pBD-ECs) are an attractive tool for cell 
therapies and tissue engineering, but have been limited by their low isolation yield. We increase 
pBD-EC yield via administration of the chemokine receptor type 4 antagonist AMD3100, as well 
as via a diluted whole blood incubation (DWBI).
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Materials & Methods—Porcine pBD-ECs were isolated using AMD3100 and DWBI and tested 
for EC markers, acetylated LDL uptake, growth kinetics, metabolic activity, flow-mediated nitric 
oxide production and seeded onto titanium tubes implanted into vessels of pigs.
Results—DWBI increased the yield of porcine pBD-ECs 6.6-fold, and AMD3100 increased the 
yield 4.5-fold. AMD3100-mobilized ECs were phenotypically indistinguishable from 
nonmobilized ECs. In porcine implants, the cells expressed endothelial nitric oxide synthase, 
reduced thrombin-antithrombin complex systemically and prevented thrombosis.
Conclusion—Administration of AMD3100 and the DWBI method both increase pBD-EC yield.
Keywords
AMD3100; biocompatible materials; cell Isolation; cell therapy endothelial cells; endothelial 
progenitor cells; swine; thrombosis; tissue engineering
Autologous endothelial progenitor cells (EPC), obtained from peripheral blood, are a 
potentially valuable source of endothelial cells for the treatment of various cardiovascular 
diseases, for example, limb ischemia [1]. In addition to their neovascularization potential, 
blood-derived EPCs hold promise for engineering solid organs that require an extensive 
blood supply. Peripheral blood-derived EPCs are now broadly categorized as either early-
outgrowth EPCs [2] or late-outgrowth EPCs [2]. The latter are the most promising cells for 
ex vivo expansion and endothelial cell replacement. Late-outgrowth EPCs are highly 
proliferative, lack the leukocyte marker CD45, and have also been referred to as endothelial 
outgrowth cells (EOC) [2–4], endothelial colony-forming cells (ECFC) [5], and blood-
derived endothelial cells (EC) [6]. We will use the term peripheral-blood derived endothelial 
cells (pBD-EC) in this study.
Despite their potential, the therapeutic application of pBD-ECs has been hindered by the 
difficulty to isolate sufficient numbers of pBD-ECs from blood for clinical- scale use. The 
average yield has been approximately 0.4 pBD-EC colonies per 20 ml human peripheral 
blood utilizing density gradient centrifugation – the ‘traditional method’ for isolation of 
progenitor cells [7,8].
We hypothesize that the yield of functional pBD-ECs for autologous cell therapies and 
tissue engineering can be increased by mobilization of progenitor cells using the chemokine 
receptor type 4 (CXCR4)-antagonist AMD3100, as well as by an isolation technique that 
reduces the number of steps and related cell loss. We recently developed the diluted whole 
blood incubation (DWBI) method in which diluted whole blood with the addition of human 
serum and growth factors is directly incubated on surfaces. This method avoids positive or 
negative selection steps that invariably lead to the loss of putative progenitor cells and 
resulted in yields of 7.0 ±2.5 EC colonies derived from 10 ml of human umbilical cord 
blood [6].
Although initially studied as a potential therapy for HIV, AMD3100 (plerixafor) was instead 
approved by the US FDA in 2008 for use in combination with G-CSF for the treatment of 
patients with non-Hodgkin’s lymphoma or multiple myeloma to mobilize hematopoietic 
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stem cells (HSC) [9]. The mobilized HSCs are collected from the patient’s peripheral blood 
and used for autologous transplantation.
AMD3100 is a bicyclam small molecule that mobilizes HSCs from bone marrow by 
competitively binding the CXCR4 on HSCs. The CXCR4 on HSCs normally binds on the 
surfaces of bone marrow stromal cells expressed ligand CXCL12, aka SDF-1 [10]. SDF-1 
binding causes CXCR4 G-protein activation, Ca2+ influx and receptor internalization, which 
directs HSCs to the bone marrow niche; disruption of that signal by AMD3100 allows those 
HSCs to instead enter the peripheral blood [11]. The most common side effects of 
AMD3100 observed in clinical trials include nausea and diarrhea in 10% of patients [12].
To date, it is unclear if the progenitor cells that give rise to pBD-ECs reside in bone marrow. 
Current evidence suggests that the late-outgrowth EPCs are derived from the vessel wall 
[7,13,14]. AMD3100-mobilized cells may thus constitute a cell population which is different 
from the progenitor cells that grow out pBD-ECs. To investigate any possible differences in 
these cell populations, we used rigorous tests under flow conditions ex vivo and in vivo to 
compare pBD-ECs isolated from late-outgrowth EPCs from pigs with or without AMD3100 
treatment.
We chose pigs for our in vivo study because of the following reasons: they are the preferred 
large animal model for cardiovascular diseases [15], we have previously characterized pBD-
ECs and found them to be phenotypically and functionally analogous to human blood-
derived ECs [6,16,17], and pigs enabled us to transplant autologous cells into the pigs’ 
aortae and inferior vena cavae (IVCs) to test cell functionality under flow in vivo. In vivo 
studies presented here provide proof-of-concept for utilizing DWBI and AMD3100-
mobilized pBD-ECs for autologous cell therapies by demonstrating that pBD-ECs remain 
functional under flow on the surface of implanted intravascular titanium (Ti) tubes, prevent 
thrombosis in the IVC locally and also reduce the coagulation response systemically.
Our results show that AMD3100 and the DWBI method independently and significantly 
increase the yield of pBD-ECs. pBD-ECs isolated from animals treated or untreated with 
AMD3100 were found to be phenotypically and functionally identical. If these pBD-ECs 
should indeed originate from blood vessels, our results cannot rule out the possibility that 
AMD3100 mobilizes pBD-ECs or their progenitor cells directly from vessel walls.
Materials & methods
AMD3100 crossover trial in swine
Animal experimentation was approved by the Duke University Institutional Animal Care 
and Use Committee. Female Yorkshire swine were used for all studies. To account for 
variability in the mobilization response between pigs, each pig served as its own control. 
Specifically, each of six pigs (~15 kg) sequentially received four subcutaneous gluteal 
injection of which two injections consisted of sham injections (controls) and two consisted 
of drug injections (test doses) with either a high dose (0.75 mg/kg) or a low dose (0.24 
mg/kg) of AMD3100 (Sigma-Aldrich, MO, USA). The control injections consisted of 
phosphate buffered saline (PBS) solution and were followed by cell isolations with either 
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2% fetal bovine serum (FBS; Gemini Bio-Products, CA, USA) or 2% porcine serum (PS; 
Gemini Bio-Products). All drug injections were followed by cell isolations with 2% PS.
Each injection–blood draw sequence was separated by 1 week to ensure that there was no 
residual drug effect and that the blood volume was replenished. Eight hours following each 
injection, the pigs underwent blood draws as previously described [16] and 60 ml of blood 
was anticoagulated with 20 ml citrate dextrose solution (Pall Corporation, CA, USA). The 
six pigs were divided into three groups of two pigs, with the order of the four injections 
randomized for each group (Figure 1). Of the two sham injections for each pig, the pBD-
ECs isolated following one of them was cultured in FBS and the other in PS.
In a separate experiment, seven more pigs were utilized to determine the optimal PS 
concentration in EC medium. EC medium was prepared by supplementing EBM-2 medium 
(Lonza, Basel, Switzerland) with EGM-2 SingleQuots Kit (Lonza), but substituting either 
2% for the FBS contained in the SingleQuots Kit.
pBD-EC isolation with traditional density centrifugation method
The mononuclear cell (MNC)-containing layer of anticoagulated blood was collected via 
density centrifugation: anticoagulated blood was diluted 1:1 with Hank’s balanced salt 
solution (Lonza) and layered on equal volumes of Histopaque-1077 (Sigma-Aldrich), 
centrifuged (30 min, 740 g, low break) and the MNC-containing layer collected and diluted 
1:1.5 in wash medium (MCDB-131, Invitrogen, CA, USA, with 2% PS, Gemini Bio-
Products), then centrifuged × 2 (10 min, 515 g, low break). MNCs were then resuspended in 
full EC medium and incubated in collagen precoated 12-well tissue culture polystyrene 
plates (Corning Costar, MA, USA, with Type-1 calf skin collagen, Sigma-Aldrich, as 
previously described [6]) at 37°C, 5% CO2. Medium was changed every 24 h for the first 4 
days, and subsequently every other day. All isolated pBD-ECs were cryopreserved in −80°C 
until used for experiments.
pBD-EC isolation with DWBI method
Porcine blood was harvested and anticoagulated with 20 USP heparin/ml blood (APP 
Pharmaceuticals, IL, USA) and then diluted 1:4 with full EC medium. Thirty milliliter of 
this final solution was added to a 100 mm × 15 mm polystyrene petri dish (Celltreat, MA, 
USA), which had been precoated with Type I collagen as described above. Following, 
diluted whole blood was incubated at 37°C and 5% CO2 and non-adherent cells and plasma 
were slowly removed every 24 h and replaced with 10 ml of new medium. On the 4th day, 
the adherent cells were gently washed once with medium and new medium was added every 
other day.
Traditional versus DWBI method trial in swine
Twenty-two pigs (~47.5 kg) were used to collect 24 ml of blood per pig and 12 ml of each 
sample (anticoagulated as described above) was used for pBD-EC isolation according to the 
‘traditional method’ and the other 12 ml for pBD-EC isolation according to the DWBI 
method. Seven days after isolation, the number of pBD-EC colonies was determined. A 
colony was defined as a group of at least 100 contiguously growing cells with pBD-EC 
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morphology as determined by light microscopy. Examples of such colonies can be seen in 
Figure 2C&D.
pBD-EC characterization with flow cytometry/acetylated LDL uptake
Isolated colonies prior to cryopreservation were evaluated with flow cytometry for CD31, 
CD105 and CD146, as well as the leukocyte markers CD14 and CD45, and CD106. Cells 
were labeled with fluorescein isothiocyanate (FITC) directly conjugated mouse antiporcine 
CD14 (MCA1218F, Serotec, Oxford, UK), CD45 (MCA1222F, Serotec), CD31 
(MCA1746F, Serotec), CD105 (ab53318, Abcam) CD106 (APG106F, Antigenix America, 
NY, USA) and CD146 (MCA214FT, Serotec) antibodies. Respective isotype controls were 
used (MCA691F and MCA928F, Serotec). A FACS-Calibur flow cytometer (Becton 
Dickinson, NJ, USA) was used for analysis as previously described [18].
pBD-ECs were further tested for uptake of DiI-labeled acetylated low-density lipoprotein 
(DiI-Ac-LDL, Biomedical Technologies, MA, USA) according to manufacturer’s 
instructions [6].
Redox assay
The metabolic activity of the four groups of pBD-ECs derived from animals in the 
AMD3100 crossover trial (high- or low-dose AMD3100, controls followed by cell isolation 
with 2% FBS or 2% PS) was compared with the alamarBlue redox assay (Invitrogen) as 
previously described [16].
Growth curves
Growth curves were created with pBD-ECs isolated from under four different conditions: 
traditional method and AMD3100-treated animals (from three pigs at passage 6); traditional 
method without AMD3100 (from three pigs at passage 5 and three pigs at passage 6); with 
the DWBI method and AMD3100-treated animals (from three pigs at passage 6); with the 
DWBI method without AMD3100-treated animals (from three pigs at passage 6 and three 
pigs at passage 9).
For all four conditions, cells were seeded into 6-well plates (Corning, MA, USA, 4×103 
cells/cm2) and the number of cells per well was quantified in phase-contrast images (Leica 
DMI3000 B) with ImageJ software (NIH) after 24, 48 and 72 h of incubation (at 37°C, 5% 
CO2 in EC medium containing 2% PS). The population doubling time (PDT) was calculated 
as:
(Equation 1)
where PN and PN+1 are cell counts at different times after seeding, and t is the time between 
PN and PS.
Flow experiment & nitric oxide quantification
Prior to flow experiments, glass slides (Becton Dickinson) were cleaned in 2% sodium 
dodecyl sulfate, rinsed in deionized water, sterilized by steam autoclaving at 121°C for 30 
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min (Steris, Amsco Century, OH, USA) and precoated with fibronectin (Sigma-Aldrich, 
0.25 µg/cm2 × 45 min at 21°C). pBD-ECs were then seeded (2.6 × 104 cells/cm2 in EC 
medium) onto two glass slides per experiment and incubated (37°C, 5% CO2, 24 h). 
Following, one of the two glass slides was designated as a static control and transferred to a 
quadriPERM cell culture vessel (Greiner Bio-One, Frickenhausen, Germany, in 10 ml of EC 
medium), and incubated. The other glass slide was inserted into a parallel plate flow 
chamber [19] in a flow circuit consisting of a 125 ml reservoir (Cole Parmer, Pyrex, IL, 
USA), peristaltic pump (L/S variable-speed economy drive and Easy Load Pump Head; 
Masterflex, IL, USA), and pulse dampener (Masterflex) in EC medium (total circuit volume 
100 ml). pBD-ECs in our parallel plate flow chamber were exposed to a shear stress of 25 
dynes/cm2 calculated according to
(Equation 2)
where τ denotes the wall shear stress (dynes/cm2), μ the medium viscosity at 37°C (0.01 
g/cm/s), w the channel width (2.5 cm), h the channel height (0.04 cm), Q the volumetric 
flow rate (cm3/s) [19].
After 48 h, glass slides were fixed in 10% formalin (Medical Chemical Corporation, CA, 
USA), then stained for CD31 and nuclei with Hoechst dye. Four random images were taken 
per slide to measure cell angles (ImageJ) with respect to the direction of flow. In order to 
measure NO production under flow and static control, two replicate medium samples were 
collected from both the flow circuit (0.5 ml) and static control (0.3 ml) in the quadriPERM 
flask (Greiner Bio-One) at 0, 1, 24 and 48 h since the start of flow.
The concentration of the NO metabolite nitrite (NO2−) was measured by chemiluminescence 
with an Ionics/Sievers Nitric Oxide Analyzer (NOA 280; Sievers Instruments, CO, USA) as 
described previously [6,20,21]. The total amount of nitrite produced per EC was calculated 
using the following equation:
(Equation 3)
pBD-EC implantation into swine
pBD-ECs isolated with the DWBI method were seeded onto Ti tubes and implanted into 
each of the four pigs from which the cells had been derived. The cells were fluorescently 
labeled prior to implantation with PKH26 (Sigma-Aldrich) [17]. Four pigs received IVC 
implants (grade 2; Tico Titanium, MI, USA, pre-sectioned and reassembled as previously 
described) [17].
These Ti implants were 4.5 cm long, 1.27 cm in outer diameter, 0.94 cm in inner diameter, 
polished on the inside surfaces and presectioned. Ti tubes were directly inserted into the 
IVCs without use of an artificial graft following our established methods [17,22]. All four Ti 
tubes were seeded with autologous pBD-ECs (2.4 × 106 cells/ml in 4.5 ml of medium) 
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derived with the DWBI method; however, in two of the four implants the cells had 
additionally been mobilized with AMD3100 (0.5 mg/kg). Four pigs received bare metal 
uncoated Ti implants as controls without pBD-ECs.
Systemic response of pBD-ECs in porcine model
We obtained blood samples from pigs’ ear veins immediately before surgery and 3 days 
postsurgery, and measured thrombin-antithrombin complex according to manufacturer’s 
instructions (Enzygnost TAT micro, Dade Behring, Germany) [23].
Immunohistochemistry/ microscopy
After explantation, Ti tubes and surrounding vessel segments were fixed in 3.7% 
paraformaldehyde (Sigma-Aldrich) and disassembled to evaluate for presence of prelabeled 
cells. Cell borders were additionally stained with antiporcine CD31 (APG311, Antigenix 
America) and secondary goat antirabbit antibody (AlexaFluor546, A-11035, Invitrogen). 
Adherent cells were tested for expression of endothelial nitric oxide synthase (eNOS) by 
permeabilizing with 0.1% Triton X (Sigma-Aldrich) followed by incubating with rabbit 
antipig eNOS antibody (ab5589; Abcam) and secondary goat antirabbit AlexaFluor488 
(A-11008, Invitrogen). Nuclei were counterstained with DAPI (Vector Laboratories).
Statistical analysis
The number of pBD-EC colonies in the AMD3100 crossover trial was compared with a 
Generalized Estimating Equation (GEE, SAS version 9.3, NC, USA). To account for 
unequal variance, a square root transformation was performed. The fraction of colonies with 
EC morphology when isolated using 2% PS versus 2% FBS was compared using Fisher’s 
exact test (GraphPad Prism 5, CA, USA). The metabolic activity of groups evaluated with 
the alamar-Blue assay was compared with one-way ANOVA (SAS). To compare the pBD-
EC isolation counts with the traditional isolation method to the DWBI isolation method, the 
Wilcoxon signed rank sum test was used (SAS). The angles of cell orientation respective to 
the direction of flow were evaluated with the Kolmogorov–Smirnov test (OriginPro 9, MA, 
USA). The longitudinal data of PDTs as well as NO production under static and flow 
conditions were analyzed with the between estimator of a panel data model (R 3.0.2, 
Vienna, Austria) [24]. The Wilcoxon rank sum test was used to analyze TAT values for bare 
uncoated Ti implants and pBD-EC-coated implants in the IVC. A significance level of 0.05 
was assumed for all tests.
Results
AMD3100 crossover trial in swine
Subcutaneous administration of AMD3100 in the crossover trial of six swine significantly 
increased the number of pBD-EC colonies as compared with PBS control injections into the 
same pigs (0.750 ±0.047 colonies per 10 ml blood vs 0.167 ±0.021 colonies per 10 ml 
blood, p < 0.0001, GEE, Figure 2A). Although the dose-dependent effect of AMD3100 did 
not reach statistical significance, more colonies were isolated with the higher dosage of 
AMD3100 (0.75 mg/kg) than with the lower dosage (0.24 mg/kg) for each pig (0.972 
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±0.104 colonies per 10 ml blood vs 0.528 ±0.073 colonies per 10 ml blood, p = 0.234, 
square root transformation followed by GEE).
The type of serum (PS vs FBS) did not significantly impact the absolute number of pBD-EC 
colonies isolated for a given volume of blood (0.250 ±0.055 colonies per 10 ml blood vs 
0.083 ±0.015 colonies per 10 ml blood, p = 0.478, square root transformation followed by 
GEE), nor the percentage of colonies with EC morphology. Although 9 of 30 colonies had 
EC morphology when using 2% PS while only 3 of 33 colonies had EC morphology when 
using 2% FBS, that difference was not statistically significant (p = 0.053, two-tailed Fisher’s 
exact test).
Traditional versus DWBI method trial in swine
When comparing the DWBI method of pBD-EC isolation to the traditional method using 
blood isolated from 22 pigs, we found that the DWBI method yielded more pBD-EC 
colonies (3.26 ±1.09 colonies per 10 ml blood) than the traditional method (0.49 ±0.20 
colonies per 10 ml blood, p < 0.005, Wilcoxon signed rank sum test, Figure 2B).
Characterization of pBD-ECs under static conditions
Flow cytometry confirmed the presence of CD31, CD146, CD105 and the absence of CD14, 
CD45 and CD106 in pBD-ECs isolated from animals treated or untreated with AMD3100 
(Figure 3). pBD-ECs also equally took up DiI-Ac-LDL, whether isolated with or without 
AMD3100 mobilization, or using the traditional or DWBI methods (Figure 4A–C).
A study of the growth kinetics revealed that cells isolated under the four different conditions 
– with the traditional method from animals treated or untreated with AMD3100, and with 
the DWBI method from animals treated or untreated with AMD3100 – had similar growth 
patterns (Figure 4D). The cells isolated with the traditional method from animals treated or 
untreated with AMD3100 had PDTs of 0.68 ±0.04 days and 0.90 ±0.15 days, respectively, 
while the PDTs for cells isolated with the DWBI method from animals treated or untreated 
with AMD3100 were 0.83 ±0.13 days and 1.14 ±0.20 days, respectively.
Any differences between the PDTs of these groups were not significant, whether comparing 
isolation using the DWBI and traditional methods (p = 0.21, between estimator of panel 
data), or whether the pBDECs were mobilized by AMD3100 or not mobilized (p = 0.12, 
between estimator of panel data).
The alamarBlue redox assay (Invitrogen) demonstrated that there was no significant 
difference in metabolic activity in pBD-ECs, regardless of whether they were isolated with a 
high dose or a low dose of AMD3100, or if the isolation was achieved from animals 
untreated with AMD3100 in medium containing either PS or FBS (p = 0.438, one-way 
ANOVA, n = 3, Figure 4E).
Characterization of pBD-ECs under fluid flow conditions
pBD-ECs that are grown to confluence on the surface of a fibronectin-coated microscope 
slide are initially randomly oriented (Figure 5A). However, exposure to 25 dynes/cm2 of 
fluid shear stress for 48 h aligned the major axes of the cells in the direction of the flow, 
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consistent with an endothelial cell phenotype (Figure 5B). This effect was seen for pBD-ECs 
isolated from animals treated or untreated with AMD3100 via the traditional method (cells 
from animals treated with AMD3100: 14.3 ±13.6°, cells from untreated animals: 9.5 ±10.8°, 
Figure 5C) as compared with their corresponding static controls (cells from animals treated 
with AMD3100: 46.6 ±25.0°, p < 0.0001, Kolmogorov–Smirnov test; cells from untreated 
animals: 47.2 ±26.7°, p < 0.0001, Kolmogorov–Smirnov test, Figure 5C). In addition to 
alignment under flow, pBD-ECs from both groups also increased NO production 
approximately tenfold after 18 h at 25 dynes/cm2 under shear stress (p < 0.01, between 
estimator of panel data model, Figure 5D). At 24 h, nitrite production/106 pBD-ECs was 
4.57 ±1.56 (for no drug, static), 56.9 ±34.6 (for no drug, flow), 5.23 ±6.40 (for AMD3100, 
static) and 43.1 ±20.3 (for AMD3100, flow). At 48 h, nitrite production/106 pBDECs was 
8.16 ±2.55 (for no drug, static), 72.6 ±35.1 (for no drug, flow), 6.27 ±6.59 (for AMD3100, 
static) and 43.7 ±31.4 (for AMD3100, flow). pBD-ECs isolated from animals treated or 
untreated with AMD3100 exhibited no discernible functional differences in their production 
of NO (p = 0.362, between estimator of panel data model).
Short-term inferior vena cava (IVC) implantation study
pBD-ECs were isolated with the DWBI method after AMD3100 mobilization and implanted 
into the IVC of those pigs from which the cells had been derived. Three days after 
implantation, all four Ti tubes coated with autologous pBD-ECs were clot-free (Figure 6A). 
On the other hand, two control implants with bare, uncoated Ti tubes in two other pigs were 
completely or partially clotted (Figure 6B).
CD31 and eNOS staining of the ECs on the cell-coated Ti tubes was performed after 
explanation and confirmed that the ECs spread to confluency and maintained their 
endothelial cell phenotype (Figure 6C).
Systemic response to autologous pBD-ECs in porcine model
TAT was measured by an enzyme immunoassay (Enzygnost TAT micro) in all pigs 
receiving IVC implants immediately before surgery and 3 days post-surgery. Over that time 
period, the pigs with bare metal Ti implants exhibited a significantly greater increase in TAT 
(5.18 ±1.62 µg/mg) than the pigs with pBD-EC-coated implants (0.40 ±0.75 µg/mg, p < 
0.05, Wilcoxon rank sum test, Figure 6D).
Discussion
One of the limitations of utilizing autologous pBD-ECs is the low yield of isolation. Our 
results show that this problem may be overcome by improving the isolation technique 
through removal of centrifugation steps and instead directly plating diluted whole blood. 
Additionally, progenitor cells may be mobilized with AMD3100, which has been shown in 
previous studies to mobilize hematopoietic stem cells for clinical applications [25,26]. 
AMD3100 is an attractive agent for translation of pBD-EC therapies into clinical practice 
because its maximal mobilization is achieved approximately 9 h after administration of a 
single subcutaneous injection in humans [27]. Consequently, Shepherd et al. tested if 
AMD3100 would mobilize human pBD-ECs in a well-designed clinical study and reported a 
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10.2-fold increase of pBD-ECs following AMD3100 administration [28]. These results were 
interpreted as bone-marrow mobilization of progenitor cells giving rise to pBD-ECs. 
Similarly, Pitchford et al. concluded that AMD3100 causes the egress of progenitor cells 
from bone marrow after conducting isolated murine hind limb perfusion experiments [29]. 
In their system, the femoral artery and vein were cannulated in order to isolate the tibia bone 
marrow from other tissues. However, this experimental setup did not exclude the vasculature 
and other studies suggest a vascular origin of pBD-ECs. Lin et al. collected peripheral blood 
from sex-mismatched bone marrow transplant patients and found that approximately 95% of 
pBD-ECs grown out from blood initially expressed the recipient genotype, but after 4 weeks 
this percentage was reversed with the vast majority of cells expressing the donor genotype 
[30]. It was concluded that most pBD-ECs were vessel-derived but highly proliferative rare 
cells existed in bone marrow. Recently, Tura et al. sought to grow out pBD-ECs from 
peripheral blood and bone marrow, the latter of which did not yield any pBD-ECs and the 
authors concluded that pBD-ECs are not derived from bone marrow [14]. If true, this 
conclusion leads to the question of how AMD3100 could mobilize progenitor cells from 
bone marrow that grow out pBD-ECs. Two conceivable explanations are as follows: first, 
AMD3100-mobilized cells belong to a different population than nonmobilized cells in which 
case the pBD-ECs grown out from two different populations should exhibit functional 
differences, which we could not detect in our study, or second, AMD3100 might mobilizes 
pBD-ECs or their progenitor cells from the vessel walls. The latter theory has not been 
investigated in the literature but receives support through several facts: pBD-ECs express 
the CXCR4 receptor [31], its ligand SDF-1 is expressed in the media of blood vessels [32] 
and intravascularly administered stem cells with high concentrations of CXCR4 
preferentially home to areas of vascular injury [33]. We believe that further research into the 
mechanisms of progenitor cell mobilization with mobilizing agents may reveal the much-
debated origin of pBD-ECs.
We conducted a crossover trial in a large animal model with each animal receiving two test 
and two control injections (high- and low-dose AMD3100) in order to minimize any 
variability in the mobilization response between different pigs. We found that a significantly 
increased number of pBD-EC colonies are isolated with subcutaneous AMD3100 
administration and that these cells are phenotypically and functionally indistinguishable 
from pBD-ECs without mobilizing agent: pBD-ECs with or without mobilizing agent 
expressed typical EC markers CD31, CD105 and CD146. CD146 has also been referred to 
as the ‘gold standard’ for the selection of ECs [34]. Moreover, the absence of CD14 and 
CD45 in our pBD-ECs confirms that the isolated cells are not part of the monocyte, 
macrophage or lymphocyte lineages [35,36]. We also ruled out the possibility that ECs are 
in an activated, proinflammatory state by demonstrating the absence of the inflammatory 
marker CD106 that mediates leukocyte-endothelial cell adhesion.
pBD-ECs with or without AMD3100 mobilization exhibited similar levels of DiI-Ac-LDL 
uptake, metabolic activity and growth patterns under static culture. Since healthy ECs are 
constantly exposed to flow that is exerting a tangential shear stress on the cell surface in 
vivo, rigorous functional analyses should include assessment of pBD-EC function under 
flow conditions. We found that pBD-ECs with or without AMD3100 mobilization aligned in 
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the direction of fluid flow shear stress when exposed to a shear stress of 25 dynes/cm2, 
mimicking the magnitude of arterial shear stress. There was no statistical significant 
difference in the time-dependent production of NO between cells isolated from animals that 
were treated with AMD3100 or untreated. As expected, pBD-ECs under fluid flow shear 
stress secreted significantly more NO under flow as compared with static culture conditions 
(approximately tenfold more NO production after 48 h at 25 dynes/cm2, p < 0.01). These 
results are analogous to our prior studies with porcine pBD-ECs isolated with the traditional 
method (approximately sevenfold more NO production after 48 h at a lower shear stress of 
15 dynes/cm2) [16] and almost identical to human umbilical cord blood-derived ECs with 
the DWBI method (approximately tenfold increase in NO production after 48 h at 25 
dynes/cm2) [6].
Whereas our previous study with human umbilical cord blood demonstrated an approximate 
20-fold increase of EC isolations with the DWBI method [6], we were able to increase the 
yield from porcine blood approximately sevenfold. These differences may be due to a larger 
number of available progenitor cells in human cord blood as compared with adult pig blood. 
Nevertheless, we confirmed that cells isolated with the DWBI method are functional, based 
on their ability to spread and adhere under blood flow in pig IVCs.
In the current study the local and systemic effects of autologous pBD-ECs derived with the 
DWBI-method from animals treated or untreated with AMD3100 were evaluated in a large 
animal model. The porcine model was chosen rather than a rodent model because the large 
animal model more closely approximates potential human studies with autologous cells for 
personalized cell therapy.
We implanted pBD-EC-lined Ti tubes into the IVCs of four pigs, two of which received 
pBD-ECs mobilized by AMD3100, while the other two received pBD-ECs isolated without 
mobilization. In all four pigs, CD31 staining of the cells after explantation confirmed that 
the pBD-ECs spread to confluence under flow conditions in vivo and maintained their 
endothelial cell phenotype. Additionally, pBD-EC function was confirmed 3 days after 
implantation into the IVC by positive staining for eNOS, indicating the presence of the EC-
specific NO secreting enzyme in vivo (Figure 6D). Since pBD-ECs had been prelabeled with 
PKH26 before implantation, we were able to rule out that adherent pBD-ECs were derived 
from possible circulating ‘fallout’ cells that attached after implantation of Ti tubes into the 
animals.
In accordance with secretion of antithrombotic markers such as NO, the pBD-EC-seeded 
implants remained free of clot (Figure 6A). In contrast, four bare metal Ti tubes were either 
fully or partially thrombosed after 3 days (Figure 6B).
The in vivo systemic effects of pBD-ECs were evaluated by quantifying TAT production. 
TAT complexes are formed when the coagulation system is activated [37–39]. The 
coagulation activity was significantly reduced in pigs that received pBD-EC-coated Ti 
implants as compared with pigs that received bare metal Ti implants (Figure 6D). These 
results demonstrate that autologous pBD-ECs not only reduce clot formation locally, but 
also exert beneficial effects systemically.
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Our study has several limitations. We were unable to establish a significant benefit of the 
use of allogenic serum (PS) as compared with xenogenic serum (FBS); however, we noticed 
a trend with allogenic serum producing lower numbers of ‘contaminating cells’ with non-EC 
morphology (see Figure 2F, colony representative of cells with non-EC morphology). We 
speculate that this observation may be due to different growth factors in xenogenic serum 
and proceeded to only utilize PS for our experiments in pigs.
In our analysis, the 1.8-fold increase in number of pBD-EC colonies with higher doses of 
AMD3100 as compared with lower doses was not statistically significant (p = 0.234), likely 
because of the limited number of six pigs in the AMD3100 crossover trial. We also did not 
quantify the increased yield if AMD3100 mobilization and the DWBI method are combined; 
rather we found that the DWBI method increased yield approximately 6.6-fold (p < 0.005) 
and AMD3100 mobilization approximately 4.5-fold (p < 0.0001), independent of each other.
Further improvements in isolation technique in conjunction with the use of mobilizing 
agents may solve the low-yield problem of utilizing pBD-ECs for the purpose of tissue 
engineering replacement organs and in the clinical setting. Future studies should expand the 
established animal model to long-term in vivo studies and to clinical studies focusing on 
patient groups that would benefit most from autologous EC therapies.
Conclusion
To increase pBD-EC isolation yield to the scale necessary for clinical cell therapies, we 
administered AMD3100 prior to blood draw and developed a novel DWBI method for cell 
culture. Those interventions increased the isolation yield of pBD-ECs from porcine 
peripheral blood 4.5-fold and 6.6-fold, respectively. The isolated pBD-ECs were fully 
functional as demonstrated through in vitro and in vivo experiments. Our findings augment 
the therapeutic potential of pBD-ECs for cardiovascular diseases as we have demonstrated 
their ability to prevent thrombosis when seeded onto titanium implants.
Future perspective
pBD-ECs are a promising tool for cell therapies. Aided by improved yield during isolation 
due to AMD3100-induced mobilization and DWBI, we predict that autologous pBD- ECs 
will be utilized for cell therapies to repair vascular damage, as well as lining the blood-
contacting surfaces of implants such as stents, grafts, and ventricular assist devices to 
prevent thrombosis and improve biocompatibility. In addition, the neovascularization 
capability of pBD-EC also holds significant potential for the engineering of solid organs that 
require an extensive blood supply.
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• Peripheral blood-derived endothelial cells (pBD-ECs) are an attractive tool for 
treatment of cardiovascular diseases, but such therapies have been hindered by 
low cell isolation yields.
Results
• Isolation yield of porcine pBD-ECs is increased by AMD3100 administration 
before blood draw as well as culturing the cells using a novel diluted whole 
blood incubation method. Isolated pBD-ECs were fully functional and 
antithrombotic, as demonstrated through in vitro and in vivo experiments.
Discussion
• AMD3100 administration and the diluted whole blood incubation cell culture 
method enhance the therapeutic potential of pBD-ECs for cardiovascular 
diseases.
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Figure 1. Timeline of crossover trial testing AMD3100 injection prior to peripheral blood-
derived endothelial cell isolation, as well as comparing porcine serum to fetal bovine serum
Six pigs each received four different injections followed 8 h later by a 60 ml blood draw to 
isolate peripheral blood-derived endothelial cell (pBD-ECs) using the traditional method. 
For each pig, those four injection–blood draw sequences were separated by 1 week to ensure 
that there was no residual drug effect and that the blood volume was replenished. The four 
injections consisted of two phosphate buffered saline sham injections (control), a high dose 
(0.75 mg/kg) of AMD3100 and a low dose (0.24 mg/kg) of AMD3100. Pigs were divided 
into three groups of two pigs, with the order of the four injections randomized for each 
group as displayed in the figure. Of the two sham injections for each pig, the pBD-ECs 
isolated following one of them were cultured in FBS and the other in PS.
FBS: Fetal bovine serum; PS: Porcine serum.
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Figure 2. Isolation of peripheral blood-derived endothelial cell colonies
(A) Number of pBD-EC colonies per 10 ml blood isolated using the traditional method with 
and without AMD3100 mobilization (high and low dose combined) in the crossover study of 
six pigs. Each blood draw collected 60 ml. Blood from pigs that received AMD3100 yielded 
significantly more pBD-EC colonies than controls (*** p < 0.0001, square root 
transformation followed by generalized estimating equation). (B) Number of pBD-EC 
colonies per 10 ml blood that were isolated using the traditional isolation method and the 
DWBI method. 24 ml of blood was drawn from each of 22 pigs; 12 ml of each blood draw 
underwent the traditional isolation method, while 12 ml underwent the DWBI isolation. A 
significantly greater number of pBD-EC colonies were observed with the DWBI method 
than with the traditional method (** p < 0.005, Wilcoxon signed rank sum test). Each error 
bar represents the SEM. (C) Colony observed at day 8 isolated from blood using the 
traditional method (without AMD3100 mobilization). (D) Colony observed at day 8 isolated 
from blood using the DWBI method (without AMD3100 mobilization). (E) Cells with 
representative endothelial cell (EC) morphology at day 8, isolated from blood using the 
traditional method (without AMD3100 mobilization). (F) Cells with representative non-EC 
morphology at day 8, isolated from blood using the traditional method (without AMD3100 
mobilization).
DWBI: Diluted whole blood incubation; pBD-EC: Peripheral blood-derived endothelial cell.
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Figure 3. Flow cytometry results (see facing page)
(A) Flow cytometry results of peripheral blood-derived endothelial cell (pBD-EC) isolated 
from animals treated with AMD3100 using the traditional method. (B) Flow cytometry 
results of pBD-ECs isolated from animals without AMD3100 treatment, using the traditional 
method. (C) Flow cytometry results of pBD-ECs isolated from animals untreated with 
AMD3100 using the DWBI method.
DWBI: Diluted whole blood incubation.
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Figure 4. Characterization of peripheral blood-derived endothelial cells isolated under various 
conditions
Peripheral blood-derived endothelial cells (pBD-EC) isolated using the traditional method 
from animals receiving no drug (A), using the traditional method from animals receiving 
AMD3100 (B) and using the DWBI method from animals receiving no drug (C), all 
incorporated DiI-labeled acetylated low-density lipoprotein (DiI-Ac-LDL). (D) Growth 
kinetics of the four pBD-EC groups. The four cell groups shown are pBD-ECs isolated with: 
the DWBI method and AMD3100 injection; the DWBI without AMD3100 injection; the 
traditional method and AMD3100 injection; the traditional method without AMD3100 
injection. The population doubling times (PDT) for the four groups were: 0.83 ±0.13; 1.14 
±0.20; 0.68 ±0.04; and 0.90 ±0.15 days. The differences between the PDTs with and without 
AMD3100 were not significant (p = 0.12, between estimator of panel data), and the 
differences between PDTs of pBD-ECs isolated with the DWBI method and traditional 
method were not signficiant (p = 0.21, between estimator of a panel data model). Each error 
bar represents the SEM. (E) Measure of pBD-ECs’ metabolic activity. There were no 
significant differences in the percent reduction of alamarBlue between pBD-ECs isolated 
with AMD3100 and pBD-ECs in the control groups cultured in either FBS or PS (p = 0.438, 
one-way ANOVA).
DWBI: Diluted whole blood incubation; FBS: Fetal bovine serum; PS: Porcine serum.
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Figure 5. Characterization of peripheral blood-derived endothelial cells under fluid shear stress 
conditions
(A) Representative image of random pBD-EC orientation under static conditions (cells 
mobilized by AMD3100 shown here). (B) Representative image of pBD-EC alignment 
following 48 h of 25 dynes/cm2 fluid shear stress (cells mobilized by AMD3100 shown 
here). (C) Angles with respect to the direction of flow for pBD-ECs under both flow and 
static conditions. Static cells showed no bias, while cells under flow showed alignment. (D) 
Nitrite production was measured as surrogate marker for nitric oxide (NO). Cells under flow 
exhibited increased NO production relative to static control groups. Each error bar 
represents the SEM. The effect of shear stress was significant (** p < 0.01, between 
estimator of panel data model); however, there was no difference in NO production among 
pBD-ECs isolated from animals treated or untreated with AMD3100 (p = 0.362, between 
estimator of panel data model).
pBD-EC: Peripheral blood-derived endothelial cell.
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Figure 6. Inferior vena cava implanation study
(A) Four Ti tubes coated with pBD-ECs remained clot free after removal from pig IVCs 
three days following implantation. Those pBD-ECs were implanted in the same pigs from 
which they were derived; all the cells were isolated using the diluted whole blood incubation 
method were combined, while two of the pigs received pBD-ECs isolated following 
AMD3100 mobilization (shown here), and the other two received pBD-ECs that were 
isolated with no mobilization. (B) Bare Ti tubes implanted into the IVCs of four pigs were 
completed or partially clotted. (C) Expression of endothelial nitric oxide synthase (eNOS, 
green) by pBD-ECs (nuclei are blue) on Ti tubes after 3 days of IVC implantation. (D) TAT 
levels for each of the eight pigs receiving implants (four lined by pBD-ECs, four bare metal) 
immediately before surgery, immediately after surgery, and 3 days postsurgery. * Indicates 
pBD-ECs isolated following injection of AMD3100.
IVC: Inferior vena cava; pBD-EC: Peripheral blood-derived endothelial cell; TAT: 
Thrombin-antithrombin complex; Ti: Titanium.
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